bufadienolide

Description

bufadienolide: isolated from liushen pills; RN given for (14beta)-isomer [MeSH]

bufadienolide : The simplest member of the class of bufadienolides that is bufanolide with unsaturation at positions 20 and 22. [CHeBI]

Cross-References

ID Source	ID
PubMed CID	46173848
SCHEMBL ID	4984207
CHEBI ID	80798
MeSH ID	M0232766

Synonyms (5)

Synonym
bufadienolide
C16921
SCHEMBL4984207
bufa-20,22-dienolide
CHEBI:80798

Drug Classes (1)

Class	Description
bufadienolides	Any steroid lactone that is a C23 steroid with a six-membered lactone ring at C-17 and its substituted derivatives. They form the aglycone constituents of cardiac glycosides.

Research

Studies (47)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.13)	18.7374
1990's	5 (10.64)	18.2507
2000's	13 (27.66)	29.6817
2010's	21 (44.68)	24.3611
2020's	7 (14.89)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	5 (10.64%)	6.00%
Case Studies	1 (2.13%)	4.05%
Observational	0 (0.00%)	0.25%
Other	41 (87.23%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	1990's	2000's	2010's	post-2020
thiazoles	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene		1995	1995	29.0	low	1	0	0	0
triptolide	1	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite	2004	2004	20.0	low	0	1	0	0
r 56865	1			1995	1995	29.0	low	1	0	0	0
cinobufotalin	1			2008	2008	16.0	low	0	1	0	0
telocinobufagin	1	steroid lactone		2016	2016	8.0	low	0	0	1	0
ouabain	4	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite	2005	2021	13.5	medium	0	3	0	1
betadex	1	cyclodextrin		2002	2002	22.0	low	0	1	0	0
thapsigargin	1	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor	2021	2021	3.0	low	0	0	0	1
glycosides	2			1996	2003	24.5	low	1	1	0	0
bilirubin	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite	2012	2012	12.0	low	0	0	1	0
proscillaridin	1	organic molecular entity		1996	1996	28.0	low	1	0	0	0
beta-escin	1			2003	2003	21.0	low	0	1	0	0
bufogenin	3	epoxy steroid; steroid lactone	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor	2005	2014	15.3	medium	0	2	1	0
isoborneol	1	borneol		1994	1994	30.0	low	1	0	0	0
bufalin	5	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug	2005	2016	14.2	medium	0	3	2	0
hellebrin	1	alpha-L-rhamnoside; disaccharide derivative		2003	2003	21.0	low	0	1	0	0
cinobufagin	7	steroid lactone		2005	2021	11.9	high	0	4	1	2
bufotalin	1	steroid lactone		2021	2021	3.0	low	0	0	0	1
arenobufagin	1	steroid lactone		2016	2016	8.0	low	0	0	1	0
piperidines	1			1995	1995	29.0	low	1	0	0	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	1			2003	2003	21.0	low	0	1	0	0
phenanthrenes	1			2004	2004	20.0	low	0	1	0	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	1990's	2000's	2010's
Arrhythmia	1	2012	2012	12.0	low	0	0	1
Arrhythmias, Cardiac	1	2012	2012	12.0	low	0	0	1
Benign Neoplasms	2	2013	2016	9.5	low	0	0	2
Bladder, Overactive	1	2017	2017	7.0	low	0	0	1
Blood Pressure, High	3	1996	2009	20.7	low	1	2	0
Bradyarrhythmia	1	2018	2018	6.0	low	0	0	1
Bradycardia	1	2018	2018	6.0	low	0	0	1
Breast Cancer	1	2016	2016	8.0	low	0	0	1
Breast Neoplasms	1	2016	2016	8.0	low	0	0	1
Cancer of Prostate	1	2014	2014	10.0	low	0	0	1
Cardiac Failure	1	2009	2009	15.0	low	0	1	0
Cardiac Rupture, Traumatic	1	2003	2003	21.0	low	0	1	0
Cardiac Toxicity	1	2017	2017	7.0	low	0	0	1
Cardiotoxicity	1	2017	2017	7.0	low	0	0	1
Chronic Kidney Failure	1	1996	1996	28.0	low	1	0	0
Diabetes Mellitus	1	2009	2009	15.0	low	0	1	0
Edema-Proteinuria-Hypertension Gestosis	1	2009	2009	15.0	low	0	1	0
Experimental Neoplasms	1	2017	2017	7.0	low	0	0	1
Heart Failure	1	2009	2009	15.0	low	0	1	0
Hypertension	3	1996	2009	20.7	low	1	2	0
Kidney Failure, Chronic	1	1996	1996	28.0	low	1	0	0
Muscle Relaxation	1	2017	2017	7.0	low	0	0	1
Neoplasms	2	2013	2016	9.5	low	0	0	2
Ovine Diseases	1	1995	1995	29.0	low	1	0	0
Plant Poisoning	2	1995	2019	17.0	low	1	0	1
Pre-Eclampsia	1	2009	2009	15.0	low	0	1	0
Pregnancy	1	2009	2009	15.0	low	0	1	0
Prostatic Neoplasms	1	2014	2014	10.0	low	0	0	1
Urinary Bladder, Overactive	1	2017	2017	7.0	low	0	0	1

Safety/Toxicity (4)

Article	Year
Investigation of cytotoxic effect of the bufanolide steroid compound cinobufagin and its related underlying mechanism in brain cell models. Journal of biochemical and molecular toxicology, , Volume: 35, Issue:10	2021
Fibroblast Activation Protein α Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity. Journal of medicinal chemistry, , 07-13, Volume: 60, Issue:13	2017
Metabolites profiling of 10 bufadienolides in human liver microsomes and their cytotoxicity variation in HepG2 cell. Analytical and bioanalytical chemistry, , Volume: 408, Issue:10	2016
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. International immunopharmacology, , Volume: 3, Issue:13-14	2003

Dosage (1)

Article	Year
In vivo effects of a novel calcium antagonist (R56865) against induced epoxyscillirosidin and tulp poisoning in sheep. The Onderstepoort journal of veterinary research, , Volume: 62, Issue:3	1995